Your privacy is very important to us. When you visit our website, please agree to the use of all cookies. For more information about personal data processing, please go to Privacy Policy.

CN

Back to Latest News

HuidaGene Therapeutics Announces 13 Presentations at the Upcoming European Society of Gene and Cell Therapy (ESGCT) Annual Meeting

2023.10.09 10:00
Views:2993
Follow Us on Social Media
g3icon09.svg
g3icon08.svg
g3icon010.svg

SHANGHAI and CLINTON (NJ), October 09, 2023 – HuidaGene Therapeutics (辉大基因; Huidagene), a global clinical-stage biotechnology company focused on developing CRISPR-based programmable genomic medicines, today announced thirteen (13) presentations on Company’s various gene therapy platforms at the upcoming European Society of Gene and Cell Therapy (ESGCT) Annual Meeting to be held in Brussels, Belgium from 24-27 October, 2023. These presentations demonstrate Company’s unique HG-PRECISE® platform developing various novel genome editing tools (hfCas13X/Y, hfCas12Max, and eRBE etc) to overcome different diseases.

“We demonstrated that our proprietary CRISPR-based HG-PRECISE® platform can improve editing efficiency and reduce off-target effects, turning revolutionary science into transformational medicines for patients living with life-threatening diseases worldwide,” said Hui Yang, Ph.D., Co-Founder and Chief Scientific Advisor of HuidaGene. “I look forward to exchanging knowledge with industry colleagues at this forum.”

The full company presence highlights the breadth of the HuidaGene contribution to advancing genomic medicine and includes two oral presentations on programmable deaminase-free base editors for G and T base editing and RNA base-editor for the treatment of OTOF-related sensorineural hearing loss. HuidaGene’s presentations at 30th ESGCT Annual Meeting include:

Genetic Tools

Abstract #

Title

Date/Time

Format

Ophthalmology

RNA base-editor

P691

RNA base   editing therapy for ABCA4-associated Stargardt disease type 1

10/25; 17:00-18:15

10/26; 20:30-21:30

Poster

Gene   replacement

P448

AAV gene   replacement therapy for RPE65-mediated inherited retinal dystrophies

10/25; 18:15-19:30

10/26; 19:30-20:30

Poster

Cas13

P674

Exploring the   potential of a novel Cas13-based RNA targeting therapy for age-related   macular degeneration

10/25; 18:15-19:30

10/26; 19:30-20:30

Poster

Neurology

Cas12i

P657

Development of   a hfCas12Max-mediated gene editing therapy in a humanised mouse model of   Huntington’s disease

10/25; 17:00-18:15

10/26; 20:30-21:30

Poster

Cas12i

P678

Development of   a hfCas12Max-mediated gene editing therapy in a humanised mouse model of   Amyotrophic lateral sclerosis

10/25; 18:15-19:30

10/26; 19:30-20:30

Poster

Cas13

P658

Assessment of safety   and feasibility of a Cas13-based RNA editing therapy for MECP2   duplication syndrome in non-human primates

10/25; 18:15-19:30

10/26; 19:30-20:30

Poster

Otology

RNA   base-editor

OR85

A single AAV   packed with RNA base editor treats OTOF-mediated deafness

10/27; 11:00-13:00

Shed 2B

Oral

Myology

Cas12i

P639

Cas12 DNA   editing restores dystrophin expression and muscle function in mouse model of   Duchenne muscular dystrophy and demonstrates high editing efficiency in NHPs

10/25; 17:00-18:15

10/26; 20:30-21:30

Poster

Technology

Platform

P673

HG-PRECISE   platform improves the performance of RNA-guided nucleases

10/25; 17:00-18:15

10/26; 20:30-21:30

Poster

Platform

P690

The use of   hfCas12Max platform in gene therapy and cell therapy

10/25; 18:15-19:30

10/26; 19:30-20:30

Poster

Base editors

P672

Miniature base   editors using engineered diverse IscB proteins

10/25; 18:15-19:30

10/26; 19:30-20:30

Poster

AAV

P187

Highly specific   AAV subtypes infecting hair cells and supporting cells in the mammalian   cochlea

10/25; 17:00-18:15

10/26; 20:30-21:30

Poster

DNA   base-editor

OR14

Programmable deaminase-free   base editors for G and T base editing by engineered glycosylase

10/25; 08:30-10:30

Shed 2A

Oral

Accepted abstracts and full preliminary program is available on the ESGCT website.

“We’re thrilled to present data demonstrating the power of our novel gene-editing tools through HG-PRECISE® platform,” said Xuan Yao, Ph.D., Co-Founder, President, and GM for Greater China of HuidaGene. “All of our gene-editing tools with high editing efficiency and specificity are small enough to package into one single AAV vector. We look forward to building on the encouraging data generated to date and remain on track to initiate multiple clinical trials for different indications using various of our novel gene-editing tools early next year.”


About HuidaGene - 辉大基因

HuidaGene Therapeutics (辉大基因) is a global clinical-stage biotechnology company focusing on discovering, engineering, and developing novel gene-editing tools and gene therapies to rewrite the future of genomic medicine. Based in Shanghai and New Jersey, HuidaGene is committed to addressing patients’ needs globally with various preclinical therapeutic programs covering ophthalmology and neurology. We are currently advancing clinical programs of HG004 in inherited retinal disease caused by RPE65 mutations (which has been granted both ODD and RPDD by U.S. FDA), HG202 CRISPR/Cas13Y RNA-editing in neovascular age-related macular degeneration (nAMD), and our preclinical pipeline, including programs HG301 CRISPR/Cas12 DNA-editing in retinitis pigmentosa, HG204 CRISPR/Cas13Y RNA-editing in neurodevelopmental disease of MECP2 duplication syndrome (MDS), and HG302 CRISPR/Cas12 DNA-editing in neuromuscular diseases of Duchenne muscular dystrophy (DMD). Company’s CRISPR-based therapeutics offer the potential to cure patients with life-threatening conditions by repairing the cause of their disease. HuidaGene is committed to transforming the future of genome-editing medicine.

For more information, please visit http://www.huidagene.com

or follow us on LinkedIn at http://www.linkedin.com/company/huidagene

Related
recommendations